Monte Rosa Therapeutics, Inc. GLUE
NASDAQ · United States · Health Technology
$10.76-0.50 (-4.48%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
On September 8, Monte Rosa Therapeutics (NASDAQ:GLUE) announced that Novartis (NYSE:NVS), its partner on a VAV1-targeted drug, had dosed the first patient in a Phase 2 trial of MRT-6160 (DDY391) for people with Sjögren’s disease. That single clinical checkpoint triggers a $50 million payment to Monte Rosa and marks just the first step in a […]
All three major US stock indexes fell in late-morning trading Tuesday as oil prices climbed and inve
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Phase 2 study to be conducted in participants with Sjögren’s disease Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study Additional studies expected to evaluate the potential of MRT-6160 (DDY391) across immune-mediated diseases; Monte Rosa eligible for additional Phase 2 study initiation milestones BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE)
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.